Literature DB >> 18207121

Comparative efficacy of penalization methods in moderate to mild amblyopia.

Jaime Tejedor1, Consuelo Ogallar.   

Abstract

PURPOSE: To compare the efficacy and sensory outcome of pharmacologic and optical penalization in the treatment of moderate to mild amblyopia.
DESIGN: Randomized clinical trial.
METHODS: In an institutional setting, two- to 10-year-old children with strabismic or anisometropic amblyopia (visual acuity in the amblyopic eye at least 20/60) who were cooperative to measure visual acuity using the logarithm of the minimum angle of resolution (logMAR) crowded Glasgow acuity cards were randomized into two groups of therapy (n=35 in each group), 1% atropine, and optical penalization with positive lenses, after stratification by cause of amblyopia. Visual acuity was tested by the logMAR crowded Glasgow acuity cards, after retinoscopic refraction, and deviation angle were measured by the simultaneous prism and cover or Krimsky test. Stereoacuity was determined using the Titmus fly test and Randot preschool or Randot circles stereoacuity test. Change in visual acuity of the amblyopic eye and in interocular difference of visual acuity after six months of amblyopia therapy was the main outcome measure; stereoacuity at six months of therapy was a secondary outcome measure.
RESULTS: Thirty-one and 32 children completed the outcome examination in the atropine and optical penalization group, respectively. Average improvement in visual acuity of the amblyopic eye was larger in the atropine than in the optical penalization group (3.4 and 1.8 logMAR lines, respectively), as well as average improvement in interocular difference of visual acuity (2.8 and 1.3 logMAR lines, respectively). Better stereoacuity, but nonsignificantly different, was detected in the atropine group.
CONCLUSIONS: Atropine penalization may be considered more effective than optical penalization with positive lenses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18207121     DOI: 10.1016/j.ajo.2007.10.029

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  16 in total

Review 1.  Amblyopia.

Authors:  Stephanie West; Cathy Williams
Journal:  BMJ Clin Evid       Date:  2011-06-30

Review 2.  Amblyopia.

Authors:  Cathy Williams
Journal:  BMJ Clin Evid       Date:  2009-09-16

Review 3.  The treatment of amblyopia: current practice and emerging trends.

Authors:  Eleni Papageorgiou; Ioannis Asproudis; Gail Maconachie; Evangelia E Tsironi; Irene Gottlob
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-01-31       Impact factor: 3.117

4.  Conventional occlusion versus pharmacologic penalization for amblyopia.

Authors:  Tianjing Li; Riaz Qureshi; Kate Taylor
Journal:  Cochrane Database Syst Rev       Date:  2019-08-28

5.  Effect of chromatic contrast on stereoacuity measurement with computer-aided three-dimensional technology.

Authors:  Lingzhi Zhao; Huang Wu
Journal:  Ann Transl Med       Date:  2019-05

6.  Stereoacuity measurement using an auto-stereoscopic smartphone.

Authors:  Lingzhi Zhao; Huang Wu
Journal:  Ann Transl Med       Date:  2019-08

Review 7.  Management of amblyopia in pediatric patients: Current insights.

Authors:  Sagnik Sen; Pallavi Singh; Rohit Saxena
Journal:  Eye (Lond)       Date:  2021-07-07       Impact factor: 3.775

Review 8.  Conventional occlusion versus pharmacologic penalization for amblyopia.

Authors:  Tianjing Li; Kate Shotton
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

9.  Evaluating stereoacuity with 3D shutter glasses technology.

Authors:  Huang Wu; Han Jin; Ying Sun; Yang Wang; Min Ge; Yang Chen; Yunfeng Chi
Journal:  BMC Ophthalmol       Date:  2016-04-26       Impact factor: 2.209

10.  Randomised controlled trial of video clips and interactive games to improve vision in children with amblyopia using the I-BiT system.

Authors:  Nicola Herbison; Daisy MacKeith; Anthony Vivian; Jon Purdy; Apostolos Fakis; Isabel M Ash; Sue V Cobb; Richard M Eastgate; Stephen M Haworth; Richard M Gregson; Alexander Je Foss
Journal:  Br J Ophthalmol       Date:  2016-03-07       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.